NEA MANAGEMENT COMPANY LLC
Q2 2024 Form 13-F
TIMONIUM, MARYLAND
CIK 0001512848
· CRD 161004
· SEC-registered investment adviser
$1.3B Reported Value Total
NEW ENTERPRISE ASSOCIATES reports 18 total accounts under management (AUM). There are 18 discretionary accounts valued at $25,912,724,688, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
30 funds
· $35.6B gross asset value
Venture Capital Fund: $34.6B · Private Equity Fund: $1.0B
Source: Form ADV filed 2026-08-26
Reported value
$1.3B
Quarter over quarter
-23.4%
Holdings
41
Top-10 concentration
73.8%
Key People
Form ADV owners & control persons
Anthony Angelo Florence
MEMBER OF THE MANAGING MEMBER OF THE ADVISER
Stephanie Siegal Brecher
CHIEF LEGAL OFFICER
Sam D Cohen
CHIEF FINANCIAL OFFICER, CORPORATE FINANCE AND TAX
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $1.3B |
| Positions | 41 |
| Change in reported value | -17.5% |
| New positions | 3 |
| Exited positions | 6 |
| Position turnover | 19.2% |
| Top-10 concentration | 73.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $1.6B |
|
Q1 2026 13F
Filed May 15, 2026
|
26 | $1.8B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
27 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
29 | $1.8B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
32 | $1.3B |
|
Q1 2025 13F
Filed May 14, 2025
|
37 | $1.3B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
41 | $1.8B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
42 | $1.8B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
41 | $1.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
44 | $1.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
44 | $1.5B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
46 | $1.3B |
|
Q2 2023 13F
Filed Aug 11, 2023
|
44 | $1.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
53 | $1.4B |
|
Q4 2022 13F
Filed Feb 10, 2023
|
57 | $1.8B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
57 | $2.0B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
57 | $1.9B |
|
Q1 2022 13F
Filed May 16, 2022
|
57 | $3.5B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
58 | $4.9B |
|
Q3 2021 13F
Filed Nov 12, 2021
|
63 | $8.4B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ACLX ARCELLX INC | $206.7M | 15.55% |
| 2 | TEM TEMPUS AI INC | $160.0M | 12.04% |
| 3 | RYTM RHYTHM PHARMACEUTICALS INC | $119.5M | 8.99% |
| 4 | SVRA SAVARA INC | $98.6M | 7.42% |
| 5 | COUR COURSERA INC | $92.1M | 6.93% |
| 6 | CRSP CRISPR THERAPEUTICS AG | $85.8M | 6.45% |
| 7 | VRNA VERONA PHARMA PLC | $80.8M | 6.08% |
| 8 | NN NEXTNAV INC | $66.4M | 5.0% |
| 9 | KRRO KORRO BIO INC | $36.9M | 2.78% |
| 10 | TRVI TREVI THERAPEUTICS INC | $33.9M | 2.55% |
| 11 | GLUE MONTE ROSA THERAPEUTICS INC | $28.8M | 2.16% |
| 12 | CVRX CVRX INC | $28.4M | 2.14% |
| 13 | AUPH AURINIA PHARMACEUTICALS INC | $22.7M | 1.71% |
| 14 | NKTX NKARTA INC | $21.1M | 1.59% |
| 15 | BDTX BLACK DIAMOND THERAPEUTICS INC | $20.7M | 1.56% |
| 16 | CELC CELCUITY INC | $20.5M | 1.54% |
| 17 | PHAT PHATHOM PHARMACEUTICALS INC | $20.2M | 1.52% |
| 18 | ADAPY ADAPTIMMUNE THERAPEUTICS PLC | $16.7M | 1.25% |
| 19 | GOSS GOSSAMER BIO INC | $16.3M | 1.23% |
| 20 | NEUE NEUEHEALTH INC | $14.8M | 1.12% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.